David Schultz, MD
Family Medicine · Evansville, INNPI 1912987363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,005 of the $21,639 with a category attached, or 87.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,545 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$3K
- Amgen$3K
- AstraZeneca$1K
- Novo Nordisk$1K
- Novartis$960
- plus $10K from 54 others
Across 82 payments — averaging $45,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.6M
- AstraZeneca$86K
- GSK$39K
What the payments were for
- Speaking & faculty fees$2,36811%
- Food & beverage$19,00588%
- Education$2661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,639 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 477 | $273,572 |
| FarxigaDapagliflozin Propanediol | 213 | $180,915 |
| JardianceEmpagliflozin | 204 | $180,317 |
| OzempicSemaglutide | 119 | $147,544 |
| MounjaroTirzepatide | 126 | $134,963 |
| RexultiBrexpiprazole | 137 | $123,479 |
| JanuviaSitagliptin Phosphate | 119 | $95,922 |
| XareltoRivaroxaban | 145 | $85,148 |
| Repatha SureclickEvolocumab | 68 | $61,487 |
| TrulicityDulaglutide | 41 | $60,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $52,642 |
| MyrbetriqMirabegron | 92 | $52,050 |
| GemtesaVibegron | 140 | $49,359 |
| KerendiaFinerenone | 55 | $49,247 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 153 | $48,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $904 | $322,451630 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,326 | $237,364299 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $380 | $236,049338 claims |
| Lilly USA, LLCMounjaro, Trulicity | $556 | $195,615167 claims |
| Novo NordiskOzempic, Rybelsus | $1,101 | $163,891132 claims |
| MerckJanuvia, Verquvo, Belsomra | $768 | $133,330180 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,225 | $123,479137 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $262 | $96,873156 claims |
| GSKTrelegy Ellipta | $731 | $52,64268 claims |
| Astellas Pharma US IncMyrbetriq | $314 | $52,05092 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $49,359140 claims |
| BayerKerendia | $384 | $49,24755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- Anthony InzerelloEvansville$308K
- Carol GoodmanEvansville$123K
- J Christopher SartoreEvansville$19K
- David BrougherEvansville$18K
- Hubert ReyesEvansville$18K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.